These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25355921)

  • 21. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition.
    Wang H; Eckels DD
    J Immunol; 1999 Apr; 162(7):4177-83. PubMed ID: 10201944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.
    Wölfl M; Rutebemberwa A; Mosbruger T; Mao Q; Li HM; Netski D; Ray SC; Pardoll D; Sidney J; Sette A; Allen T; Kuntzen T; Kavanagh DG; Kuball J; Greenberg PD; Cox AL
    J Immunol; 2008 Nov; 181(9):6435-46. PubMed ID: 18941234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.
    Dazert E; Neumann-Haefelin C; Bressanelli S; Fitzmaurice K; Kort J; Timm J; McKiernan S; Kelleher D; Gruener N; Tavis JE; Rosen HR; Shaw J; Bowness P; Blum HE; Klenerman P; Bartenschlager R; Thimme R
    J Clin Invest; 2009 Feb; 119(2):376-86. PubMed ID: 19139562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution.
    Neumann-Haefelin C; McKiernan S; Ward S; Viazov S; Spangenberg HC; Killinger T; Baumert TF; Nazarova N; Sheridan I; Pybus O; von Weizsäcker F; Roggendorf M; Kelleher D; Klenerman P; Blum HE; Thimme R
    Hepatology; 2006 Mar; 43(3):563-72. PubMed ID: 16496339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL.
    Wilson CS; Moser JM; Altman JD; Jensen PE; Lukacher AE
    J Immunol; 1999 Apr; 162(7):3933-41. PubMed ID: 10201912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells.
    Frasca L; Del Porto P; Tuosto L; Marinari B; Scottà C; Carbonari M; Nicosia A; Piccolella E
    J Immunol; 1999 Jul; 163(2):650-8. PubMed ID: 10395654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8
    Song I; Gil A; Mishra R; Ghersi D; Selin LK; Stern LJ
    Nat Struct Mol Biol; 2017 Apr; 24(4):395-406. PubMed ID: 28250417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.
    Pasetto A; Frelin L; Aleman S; Holmström F; Brass A; Ahlén G; Brenndörfer ED; Lohmann V; Bartenschlager R; Sällberg M; Bertoletti A; Chen M
    J Immunol; 2012 Nov; 189(9):4510-9. PubMed ID: 23024278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.
    Quadeer AA; Louie RH; Shekhar K; Chakraborty AK; Hsing IM; McKay MR
    J Virol; 2014 Jul; 88(13):7628-44. PubMed ID: 24760894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.
    Neumann-Haefelin C; Timm J; Schmidt J; Kersting N; Fitzmaurice K; Oniangue-Ndza C; Kemper MN; Humphreys I; McKiernan S; Kelleher D; Lohmann V; Bowness P; Huzly D; Rosen HR; Kim AY; Lauer GM; Allen TM; Barnes E; Roggendorf M; Blum HE; Thimme R
    Hepatology; 2010 Jan; 51(1):54-62. PubMed ID: 20034048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein.
    Chaurasia P; Nguyen THO; Rowntree LC; Juno JA; Wheatley AK; Kent SJ; Kedzierska K; Rossjohn J; Petersen J
    J Biol Chem; 2021 Sep; 297(3):101065. PubMed ID: 34384783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase.
    Oniangue-Ndza C; Kuntzen T; Kemper M; Berical A; Wang YE; Neumann-Haefelin C; Foote PK; Hills-Evans K; Reyor LL; Kane K; Gladden AD; Bloom AK; Power KA; Thimme R; Lauer GM; Henn MR; Kim AY; Allen TM
    J Virol; 2011 Nov; 85(22):11883-90. PubMed ID: 21880756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A HLA-A2-restricted-CTL epitope variation at the N-terminal of HCV helicase and the immune response of CTLs].
    Guo HZ; Wang WL; Wang T
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):325-7. PubMed ID: 15193229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus mutation affects proteasomal epitope processing.
    Seifert U; Liermann H; Racanelli V; Halenius A; Wiese M; Wedemeyer H; Ruppert T; Rispeter K; Henklein P; Sijts A; Hengel H; Kloetzel PM; Rehermann B
    J Clin Invest; 2004 Jul; 114(2):250-9. PubMed ID: 15254592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells.
    Salloum S; Kluge SF; Kim AY; Roggendorf M; Timm J
    Antiviral Res; 2010 Aug; 87(2):272-5. PubMed ID: 20488208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.
    Nitschke K; Barriga A; Schmidt J; Timm J; Viazov S; Kuntzen T; Kim AY; Lauer GM; Allen TM; Gaudieri S; Rauch A; Lange CM; Sarrazin C; Eiermann T; Sidney J; Sette A; Thimme R; López D; Neumann-Haefelin C
    J Hepatol; 2014 Jan; 60(1):22-9. PubMed ID: 23978718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.